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Visceral obesity is frequently associated with the development of type 2 diabetes (T2D), a highly prevalent chronic disease that
features insulin resistance and pancreatic β-cell dysfunction as important hallmarks. Recent evidence indicates that the chronic,
low-grade inflammation commonly associated with visceral obesity plays a major role connecting the excessive visceral fat
deposition with the development of insulin resistance and pancreatic β-cell dysfunction. Herein, we review the mechanisms by
which nutrients modulate obesity-associated inflammation.
1. Introduction
Visceral obesity, the excessive accumulation of fat in the adi-
pose depots located inside the peritoneal cavity, is a major
risk factor for the development of several highly prevalent,
chronic diseases, namely, type 2 diabetes (T2D), cardiovascu-
lar diseases, and some types of cancer, among others [1, 2].
The increased prevalence of visceral obesity in the last
decades has dramatically raised the incidence of its associated
diseases. It was estimated, for example, that approximately
415 million people aged 20–79 years in the world had diabe-
tes, such numbers that are expected to grow to 642 million in
2040 [3]. Importantly, a large portion of either overweight or
obese individuals also present with T2D, supporting the
strong association between both diseases [4].
T2D is a heterogeneous disease that features insulin resis-
tance and pancreatic β-cell dysfunction as major hallmarks.
Insulin resistance is defined as the inability of insulin to
properly stimulate glucose uptake in skeletal muscle and adi-
pose tissue and to inhibit hepatic glucose production. Despite
of the intense research in this area, there are still some doubts
about the exact sequence of events that leads to the develop-
ment of obesity-associated insulin resistance as elegantly
reviewed in [5]. The most traditional hypothesis suggests that
either obesity or the intake of obesogenic, hypercaloric diet
promotes first insulin resistance, which then results in hyper-
glycemia followed by hyperinsulinemia. In accordance to this
hypothesis, hyperglycemia and a compensatory hyperinsuli-
nemia are major metabolic phenotypes found in the early
stages of T2D. Chronically, hyperglycemia may promote, in
a more advanced stage of T2D, pancreatic islet damage and
a subsequent decline in insulin secretion. Interestingly,
recent studies have suggested, based on findings obtained in
obese humans and rodents and patients after bariatric sur-
gery, that hyperinsulinemia, instead of hyperglycemia, is
the primary event involved in the development of insulin
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resistance and T2D. In accordance with this hypothesis,
either obesity or the intake of an obesogenic, hypercaloric
diet enhances β-cell insulin secretion and/or reduces its deg-
radation, promoting hyperinsulinemia, which chronically
results in insulin resistance and therefore hyperglycemia.
Taking into account the strong evidence supporting both of
the aforementioned hypotheses, one may argue that the exact
sequence of events involved in the development of obesity-
associated insulin resistance and T2D may vary according
to the underlying obesogenic conditions.
T2D results from a complex interaction between genetic
and environmental factors. Studies evaluating familial risks
indicate that T2D has a high 50% heritability, in which
individuals with either one affected first-degree relative or
at least two affected siblings, independently of the parental
diabetes status, are at the higher risk of developing T2D [1].
Genome-wide association studies have identified so far
more than 40 diabetes-associated loci, which are related to
β-cell function, insulin sensitivity, and obesity and respond
to approximately 10% of T2D heritability [1]. Noteworthily,
the greatest majority of T2D cases are associated with two or
more genetic mutations (polygenic nature), such alterations
that in most cases increase the propensity, but are not suffi-
cient to induce disease development without the contribution
of environmental and/or behavioral factors. The very same
rationale applies to the development of visceral obesity, a
major risk factor for T2D [2].
Inflammation is at the very centre of metabolic diseases
such as obesity, T2D, and metabolic syndrome, playing an
important role not only in their development but also as a
linking factor between them. Indeed, visceral obesity is asso-
ciated with a chronic inflammatory process of low intensity,
defined as metabolic inflammation or “metainflammation”
that affects important metabolic tissues such as adipose
tissue, liver, skeletal muscle, pancreas, intestines, and hypo-
thalamus, among others [6]. The adipose tissue, for example,
the organ that defines obesity, develops upon this condition
an inflammatory process characterized by the recruitment,
infiltration, and polarization of leukocytes to a proinflamma-
tory profile [6]. Among the leukocytes recruited to adipose
tissue upon obesity are neutrophils, macrophages, dendritic
and mast cells from the innate immune system, and sev-
eral subtypes of T and B lymphocytes from the adaptive
immune system [7]. Several stimuli were suggested to medi-
ate the induction of leukocyte recruitment to adipose tissue
found upon obesity such as the following: (1) activation of
adipocyte proinflammatory pathways by LPS and saturated
fatty acids and secretion of chemokines such as monocyte
chemoattractant protein-1 (MCP-1), (2) tissue hypoxia,
(3) adipocyte death, and (4) mechanical stress between
adipocytes and the extracellular matrix [6]. Importantly, after
recruitment, tissue leukocytes also undergo polarization to
different phenotypes. Macrophages, for example, which
account for approximately 50% of the cells composing adi-
pose tissue upon obesity, undergo during this condition a
polarization to a proinflammatory M1 phenotype [8]. These
proinflammatory leukocytes along with activated, hyper-
trophied adipocytes secrete a plethora of proinflammatory
cytokines/adipokines, chemokines, and lipids, perpetuating
inflammation and impairing tissue metabolism. Importantly,
proinflammatory mediators have been shown to induce
insulin resistance by impairing several steps in the intra-
cellular signaling cascade of this hormone [9, 10] and adi-
pose tissue macrophage depletion attenuates diet-induced
obesity, inflammation, and insulin resistance [8].
Intake of excessive amounts of nutrients is a major
underlying cause of obesity and obesity-associated compli-
cations and an important modulator of many phenotypes
associated with this condition including inflammation. We
review herein the mechanisms by which excessive intake of
nutrients chronically modulates visceral obesity-associated
inflammation with a special emphasis in the role of nutrient
sensors as likely mediators of these actions.
1.1. Nutrient Sensing. Nutrients have vital functions in cells
acting not only as metabolic substrates for energy production
but also as building blocks for the synthesis of macromol-
ecules and cellular components [11]. In the face of such
essential roles of nutrients, organisms have evolved several
mechanisms to sense levels of specific nutrients in the
extra- and intracellular compartments allowing the proper
coordination of rates of growth, proliferation, and function
according to nutrient availability [11]. Nutrient-sensing
mechanisms are found in all organisms; some of them
are well conserved through evolution being found in eukary-
otic organisms varying from yeast to mammals, whereas
others are exclusive of prokaryotes [11]. Importantly, in
multicellular organisms, some nutrient sensing mecha-
nisms also evolved to undergo regulation by the endocrine
system, allowing the coordination at whole-body level of
nutrient sensing activity among different cells/tissues,
which is of major importance in the maintenance of whole-
body homeostasis.
Proteins that have the capacity to sense fluctuations in
the concentration of a specific nutrient or a product of its
metabolism within the physiological range are denominated
as nutrient sensors [11]. Nutrient sensors, which can be
located at different cell compartments as the plasma mem-
brane, cytosol, organelle endomembranes, or the nucleus,
respond to fluctuations in nutrient levels through diverse
mechanisms varying from the activation of phosphorylation
cascades, changes in gene transcription, and enzymatic activ-
ities, among others. Upon obesity, nutrient sensors are
chronically challenged by excessive amounts of some nutri-
ents, which impact their activity and regulatory role over cel-
lular processes. More specifically, metabolomics studies have
found that visceral obesity is frequently associated with
increased serum concentrations of glucose, branched-chain
and aromatic amino acids (BCAA and AA, resp.), and several
lipids such as saturated and omega 6 fatty acids, acylcarni-
tines, and phospholipids, among others [12]. Chronic tissue
exposure to excessive amounts of some of these nutrients
has been implicated in the development of common features
of obesity and T2D such as organelle dysfunction (endoplas-
mic reticulum and mitochondria stress) and oxidative stress,
both of which being candidates as triggering factors of
obesity-associated inflammation and insulin resistance. On
the other hand, elevated intake of some nutrients such as
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ω-3 polyunsaturated fatty acids was shown to protect from
obesity-associated inflammation and insulin resistance.
1.2. Insulin Signaling and Inflammation. Insulin is a major
anabolic hormone that exerts its actions by interacting with
a receptor constituted of two extracellular α-chains contain-
ing the ligand-binding site and two transmembrane β-chains
that possess the tyrosine kinase activity. The insulin receptor
(IR) displays 50% homology to the insulin-like growth factor
receptor (IGFR), and in some cells, both receptors may form
IR-IGFR hybrids that recognize both insulin and IGF-1 as
ligands [13, 14]. Upon interaction with insulin or IGF-1,
the receptor changes its conformation and phosphorylates
at tyrosine residues itself and a family of adaptor proteins
known as insulin receptor substrates (IRS). Tyrosine-
phosphorylated IRS then binds to the SH2 domain of the
p85 regulatory subunit of the lipid kinase phosphoinositide-
3-kinase (PI3K) promoting the conversion of the membrane
lipid phosphatidylinositol 3,4-biphosphate (PIP2) to phos-
phatidylinositol 3,4,5-biphosphate (PIP3). PIP3 then binds
to and recruits protein kinase B/Akt to the cell membrane
promoting its phosphorylation at Ser473 and Thr308 by the
mechanistic target of rapamycin complex 2 (mTORC2) and
phosphoinositide dependent-kinase 1 (PDK1), respectively
[15]. Upon its phosphorylation and activation, Akt promotes
glucose uptake by phosphorylating Rab GAP TBC1D4
(AS160) inducing therefore the translocation of vesicle-
containing glucose transporter 4 (GLUT4) to the plasma
membrane [16] and inhibits hepatic gluconeogenesis by
phosphorylating and inactivating the transcription factor
forkhead box protein O1 (FoxO1) and the CREB-CBP-
CRTC2 complex, thus suppressing the expression of glu-
coneogenic enzymes phosphoenolpyruvate carboxykinase
(PEPCK) and glucose 6-phosphatase (G6Pase) [15, 17].
In addition to those actions that are susceptible to developing
resistance upon obesity and T2D, insulin, through the
sequential PI3K-Akt activation, inhibitory phosphorylation
of the complex tuberous sclerosis complex 1/2 (TSC1/
TSC2), and activation of Ras homolog enriched in the
brain (Rheb), activates the mechanistic target of rapamycin
complex 1 (mTORC1), which in turn promotes protein
synthesis by phosphorylating the ribosomal protein S6K
and eukaryotic translational initiation factor 4E-binding
protein 1 (4E-BP), among many other processes [18].
Another important signaling pathway induced by insulin
is the mitogen-activated protein kinase (MAPK), reviewed
in detail elsewhere [19], which promotes cell proliferation,
among other actions.
In healthy cells, intracellular insulin signaling is con-
stantly monitored by several regulatory checkpoints that,
through a complex system of negative feedback loops, keeps
the level of activity of this signaling pathway within the opti-
mal physiological range. One of these regulatory loops is
exerted by mTORC1 downstream substrate S6K1 that, when
phosphorylated and activated, catalyzes a negative feedback
characterized by the inhibitory phosphorylation of IRS at
serine residues, blocking its ability to interact and alloste-
rically activate PI3K [20]. Another feedback loop modulat-
ing insulin signaling catalyzed by mTORC1 involves the
phosphorylation and stabilization of the adaptor protein
GRB10, which binds via SH2 domain to the phosphorylated
tyrosine at the insulin receptor blocking the interaction with
IRS [21, 22]. In addition, GRB10 may also reduce insulin sig-
naling by promoting IRS ubiquitination via the ubiquitin
ligase E2 NEDD4.2 and proteasomal degradation [23].
Importantly, dysfunction of these regulatory systems and
feedback loops promotes chronic overactivation of intra-
cellular insulin signaling and is associated with cancer
incidence, whereas the opposite, that is, impaired insulin
signaling (resistance), defines T2D.
The mechanisms by which cells become refractory to
insulin action in obesity are not completely understood.
Compelling evidence published in the early 1990s had shed
light on this issue not only by establishing obesity as an
inflammatory disease but also by indicating that inflamma-
tory mediators may play a key role as linking factors between
excessive fat deposition and the development of insulin resis-
tance and other associated diseases [24]. More specifically, it
was shown in these studies that the proinflammatory cyto-
kine tumor necrosis factor- (TNF-) α is oversecreted by adi-
pose tissue in obesity, promotes insulin resistance in rodents,
and correlates with insulin resistance in obese children and
adults [24–27]. Furthermore, it was later shown that deletion
of TNF-α or its receptor protects mice against diet-induced
obesity and insulin resistance [28], whereas TNF-α blockade
by treatment with its monoclonal antibody infliximab
improved glucose homeostasis in patients with rheumatic
disease [29–32]. In spite of those promising findings, TNF-
α blockade was not effective in treating insulin resistance in
obese patients [33], such findings that were somehow
expected considering that inflammation is a complex process
characterized by the involvement of many protein and lipid
mediators. Indeed, subsequent studies have shown that other
proinflammatory mediators such as interleukin- (IL-) 1β, IL-
6, interferon- (IFN-) γ, ceramides, prostaglandins, and lipo-
polysaccharide (LPS) from the membrane of gram-negative
bacteria residing in gut microbiota, among others, are also
involved in the development of obesity-associated insulin
resistance [34–36]. Among those, obesity-associated eleva-
tion in the circulating levels of LPS, defined as metabolic
endotoxemia, has been considered as a major triggering fac-
tor that links excessive intake of fat and the development of
obesity-associated inflammation [35, 37]. Another important
inflammatory mediator involved in obesity is IL-1β, a cyto-
kine whose secretion requires its processing by caspase-1 as
the result of the activation of the nucleotide-binding domain,
leucine-rich-containing family, pyrin domain-containing
3 (NLRP3) inflammasome, a multimeric cytosolic protein
complex activated by pathogen-associated molecular pattern
(PAMP) and danger-associated molecular pattern (DAMP)
molecules [38]. Indeed, blockade of IL-1β actions by treat-
ment with a receptor antagonist (anakinra) or monoclonal
antibody reduces systemic inflammation and improves glyce-
mia and β-cell secretory function in T2D patients [34].
One common signaling event that is at the very centre of
obesity-associated inflammation is the activation of nuclear
factor κ-light-chain-enhancer of activated B cells (NFκB), a
conserved family of transcription factors that regulate
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inflammatory processes, immune function, development,
and growth [39]. Importantly, chronic NFκB activation
may be involved in the development of several diseases in
addition to obesity such as T2D and cancer, among others.
Five NFκB protein members are expressed in mammalian
cells, RelA (p65), RelB, c-Rel, NFκB1 (p50/105), and NFκB2
(p52/100) [39]. In the absence of stimulus, dimers of NFκB
protein members are bound to the inhibitor κB (IκB), which
maintains the NFκB complex in the cytosol, inhibiting there-
fore its translocation to the nucleus and transcriptional activ-
ity. Proinflammatory mediators activate NFκB through a
series of events that involve IκB phosphorylation by IκB
kinase (IKK), followed by its ubiquitination and proteasomal
degradation, which then release the p50/RelA (p65) dimer
for translocation to the nucleus, where it can repress or
induce gene transcription by binding to 9-10 nucleotide
sequences in DNA promoter regions denominated as NFκB
response elements [39].
Proinflammatory mediators through the activation of
several signaling pathways such as the canonical toll-like
receptor- (TLR-) IKK-NFκB, and the kinases c-Jun N-
terminal kinases (JNK), Janus kinase (JAK), and mTOR,
among others [10], promote insulin resistance by impairing
different steps in the intracellular insulin signaling cascade,
namely, by either phosphorylating IRS at inhibitory serine
residues, or inhibiting Akt dual phosphorylation and activa-
tion, or reducing AS160 phosphorylation and GLUT-4 trans-
location [9, 10, 40]. Importantly, resistance selectively affects
only few processes regulated by insulin such as glucose
uptake in myocytes and adipocytes and glucose production
in hepatocytes. Other insulin actions such as the activation
of protein synthesis and de novo lipogenesis do not seem to
be impaired in insulin-resistant conditions [40–42]. Below,
we review the molecular mechanisms by which some nutri-
ents modulate obesity-associated inflammation.
1.3. Glucose Excess (Glucotoxicity) and Inflammation.
Chronic tissue exposure to hyperglycemia, due to the ele-
vated intake of diets rich in simple carbohydrates of high gly-
cemic index and/or impaired glucose homeostasis, is
associated with the development of tissue inflammation. It
has been extensively shown, for example, in rodent adipose
tissue, liver, and pancreas, that high sucrose feeding pro-
motes an inflammatory process characterized by enhanced
leukocyte recruitment and polarization to a proinflammatory
phenotype, as well as exacerbated cytokine production and
secretion [43–47]. Similarly to rodents, acute and persistent
hyperglycemia in humans is associated with elevated circu-
lating levels of several proinflammatory cytokines and
markers of endothelial and oxidative stress [48, 49]. Fur-
thermore, human and rodent pancreatic β-cells exposed
to high glucose levels displayed NLRP3 inflammasome
and caspase-1 activation and enhanced IL-1β production
[50]. The underlying mechanisms by which exposure to high
glucose levels activates the NLRP3 inflammasome and
whether this occurs in other cell types than β-cells are
unknown and deserve to be investigated. Recent findings
stating that mitochondrial dissociation and inhibition of the
rate-limiting enzyme of glycolysis hexokinase promote
NLRP3-inflammasome activation and IL-1β in macrophages
[51] open the possibility for the involvement of this enzyme
as a mediator of glucose actions towards the NLRP3 inflam-
masome. Indeed, high glucose levels may inhibit hexokinase
by inducing cell accumulation of its allosteric inhibitor glu-
cose 6-phosphate and/or the Krebs cycle intermediate citrate,
both of which have been shown to promote inflammasome
activation in macrophages [51].
In addition to pancreatic β-cells, in vitro exposure of
endothelial cells, monocytes, macrophages, hepatocytes, adi-
pocyte progenitor cells, or mature adipocytes to high glucose
levels is associated with a proinflammatory response charac-
terized by activation of the canonical proinflammatory NFκB
signaling pathway and elevated cytokine secretion [52–56].
In terms of possible molecular mechanisms, activation of
the cellular inflammatory response by high glucose levels
has been attributed to the following processes: (1) enhanced
production of reactive oxygen species (ROS) and oxidative
stress [55], (2) activation of the MAPK pathway [54]. (3)
nonenzymatic glycation and formation of advanced glyca-
tion end products (AGE) [49], (4) activation of protein
kinase C (PKC) isoforms [57], (5) epigenetic and chromatin
modifications [52], (6) activation of transforming growth
factor- (TGF-) β-activated kinase 1 signaling [53], (7) activa-
tion of the hexosamine pathway and modification of proteins
by N-acetylglucosamine (O-GlcNAc modification) [58], and
(8) inhibition of AMP-activated protein kinase (AMPK) [59].
Among those processes, which have been covered before in
an excellent review article [60], we will further discuss herein
the mechanisms by which exposure to high glucose levels
promotes inflammation by inducing oxidative stress and
spontaneous glycation and by inhibiting the energy sensor
AMPK (Figure 1).
Chronic cell exposure to high glucose levels is associated
with an imbalance between ROS production and antioxidant
buffering resulting in cellular oxidative stress. Mechanisti-
cally, high glucose levels increase ROS production and oxida-
tive stress by enhancing glucose oxidation through the Krebs
cycle, NADH/NAD and FADH2/FAD ratios and electron
flux in a stepwise manner through complexes I and III redox
High glucose
AGEs
AGEs
RAGE
AMPKROS
Chronic inflammation
Figure 1: Main mechanisms by which glucose excess induces
chronic inflammation. AGEs: advanced glycation end products;
AMPK: AMP-activated protein kinase; RAGE: receptor for AGEs;
ROS: reactive oxygen species.
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centres, which then catalyzes the transference of some of
these electrons to O2 [49]. Oxygen radical species are highly
reactive substances that when in excess promote organelle
dysfunction and cellular damage by reacting with protein,
lipids, carbohydrates, and DNA [49]. In oxidative stress, cells
trigger an inflammatory response as a protective mechanism
to repair cell damage and avoid death that includes activation
of intracellular signaling through the NFκB pathway [61], as
well as NLRP3 inflammasome-mediated IL-1β cleavage and
secretion [62, 63].
In addition to oxidative stress, high glucose levels also
promote inflammation by enhancing the spontaneous glyca-
tion of free amino groups of proteins, DNA, and other mol-
ecules, generating, through a series of reactions, AGE [49].
Importantly, glycation is concentration-dependent, does
not require enzymatic activity, and, similarly to ROS, impairs
the biological function of molecules, inducing organelle dys-
function, stress, and inflammation. In addition to glucose,
other simple sugars such as fructose, galactose, and ribose,
as well as phosphorylated intermediates of metabolism (glu-
cose 6-phosphate, fructose 6-phosphate, ribose 5-phosphate,
etc.), are also precursors for AGE formation [49]. Several cir-
culating proteins such as albumin, insulin, hemoglobin, and
the lipoproteins LDL, VLDL, and HDL have also been shown
to undergo glycation in conditions of glucose excess, forming
precursors of AGE denominated as Amadori products [49].
Among these, glycated albumin and LDL, for example, were
shown to induce proinflammatory NFκB signaling, cytokine
secretion, and inflammation through the activation of
Amadori receptors in the target cells [64, 65]. Similarly to
its precursors, AGE exert part of their actions through the
activation of a class of ubiquitously expressed membrane
receptors of AGE (RAGE). Binding and activation of RAGE
by AGE promotes an oxidative stress-dependent proinflam-
matory cell response characterized by NFκB activation,
increased cytokine secretion, activation of cyclooxygenase
and prostaglandin synthesis, and enhanced recruitment and
activation of both innate and adaptive immune system [49,
66–68]. Supporting this notion, RAGE activation promotes
NFκB activation, IL-6 and TNF-α secretion, and polarization
of bone marrow-derived macrophages to a proinflammatory
M1 profile [69]. In contrast, RAGE deletion is associated
with reduced leukocyte recruitment and inflammation of
the peritoneal cavity in a model of thioglycollate-induced
acute peritonitis [70]. Altogether, these findings indicate that
modification of cellular constituents by ROS and/or glycation
may be responsible, at least in part for the inflammatory
response induced by hyperglycemia.
One important nutrient and energy sensor that detects
variations in cell glucose availability is the heterotrimeric
protein AMP-activated protein kinase (AMPK), a well-con-
served, ubiquitously expressed, serine/threonine kinase
whose activity is modulated by changes in ADP/ATP ratio
and cell energy status. In situations of energy scarcity, AMPK
is activated by an elevation in the ADP/ATP ratio, whereas
the opposite, that is, a reduction in AMPK activity, occurs
in situations of energy surplus and reduced ADP/ATP ratio
[71]. Mechanistically, AMPK is activated by ADP and more
potently by AMP through a process that involves the binding
of adenine nucleotides to the AMPK γ subunit. This changes
its conformation and leaves it not only prone to the phos-
phorylation at the α subunit Thr172 residue by liver kinase
B-1 (LKB-1) but also resistant to the dephosphorylation by
protein phosphatase 2A [71]. When active, AMPK promotes
glucose uptake, fatty acid oxidation, mitochondrial biogene-
sis, and other energy-generating catabolic processes and
inhibits synthetic pathways, such as fatty acid and protein
syntheses [71]. In addition to its role in the regulation of
metabolism, several pieces of evidence support a likely
involvement of AMPK as an important modulator of obesity-
and hyperglycemia-induced inflammation. Under these con-
ditions characterized by energy surplus, AMPK Thr172
phosphorylation and activity are broadly and markedly
reduced. Such a phenotype is also seen upon treatment
of bone marrow-derived macrophages and dendritic cells
with LPS and other proinflammatory molecules [72–75].
Indeed, in vitro macrophage AMPK inhibition by either
RNAi or expression of AMPK dominant negative or dele-
tion of the AMPK β1 subunit is associated with enhanced
LPS-induced TNF-α, IL-6, and cyclooxygenase-2 levels,
diacylglycerol accumulation and PKC activation [72, 74]. In
vivo, genetic AMPK inhibition in macrophages exacerbates
obesity-associated liver and adipose tissue inflammation by
increasing macrophage recruitment and polarization to a
proinflammatory M1 profile [72]. In accordance with the
notion emerged from the above-mentioned loss-of-function
studies suggesting that AMPK activity is anti-inflammatory
in nature, both in vitro and in vivo pharmacological activa-
tion of this kinase with either AICAR (5-aminoimidazole-
4-carboxamide ribonucleotide) or the antidiabetic drugs
metformin and troglitazone or the glycolysis inhibitor 2-
deoxyglucose is associated with marked attenuation of
LPS-induced NFκB activation, as well as iNOS and TNF-α
expression in myocytes, adipocytes, macrophages, neutro-
phils, and dendritic cells [75–77]. Furthermore, recent stud-
ies have found not only that AMPK activity is increased by
the anti-inflammatory molecules IL-10, TGF-β, salicylate
[74, 78], and adiponectin [79] but also that its constitutive
genetic activation in macrophages resulted in impaired pro-
duction of proinflammatory cytokines and enhanced cell
polarization to a M2 anti-inflammatory profile [74]. Mecha-
nistically, AMPK seems to exert its anti-inflammatory
actions by impairing intracellular proinflammatory signaling
through NFκB, as well as by inducing in macrophages a met-
abolic shift from aerobic glycolysis to oxidative pathways
[74]. Altogether, these findings establish AMPK as an impor-
tant pharmacological target to counteract obesity and
hyperglycemia-associated inflammation.
1.4. Amino Acid Excess and Inflammation. Metabolomic
characterization of the serum of fasting obese insulin-
resistant patients indicates that elevated circulating levels of
branched-chain (leucine, isoleucine, and valine) and aro-
matic (phenylalanine, tyrosine, and tryptophan) amino acids
(BCAA and AA, resp.) are not only important metabolic sig-
natures that distinguish obese patients from lean, healthy
individuals [12, 80, 81] but also risk factors for the develop-
ment of insulin resistance and T2D [82, 83]. Despite those
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findings, it is still unknown whether BCAA have a causal role
in the development of obesity-associated insulin resistance or
whether elevated circulating levels of BCAA are just a
metabolic consequence of this disease. In line with a pos-
sible causal contribution, supplementation of a high-fat
diet with all three BCAA has deleterious effects on insulin
sensitivity in rats [81, 84] and BCAA infusion to healthy man
impaired insulin-stimulated glucose disposal in skeletal mus-
cle [85]. Furthermore, treatment of myocytes and murine
and human adipocytes with amino acids in vitro also induces
insulin resistance [85, 86]. Mechanistically, this deleterious
effect of BCAA on insulin sensitivity involves the activa-
tion of the nutrient and amino acid sensor mTORC1
that promotes insulin resistance by activating S6K1 and
therefore the inhibitory phosphorylation of IRS-1 at serine
residues. Importantly, mTORC1 is overactivated in adi-
pose tissue, liver, and skeletal muscle of diet- and genetic-
induced obese, insulin-resistant rodents [87, 88]. Another
mechanism by which mTORC1 overactivation may impair
IRS-1 function and induce insulin resistance is through the
activation of c-JUN-N terminal kinase (JNK) as the result
of exacerbated protein synthesis, endoplasmic reticulum
(ER) stress, and unfolded protein response (UPR) [89, 90].
Despite this, it is still unclear whether BCAA are implicated
in obesity-associated mTORC1 overactivation and whether
this complex is involved in the development of obesity-
linked insulin resistance.
In favor of the notion, however, that elevated serum
BCAA levels are rather a consequence of obesity and insulin
resistance, both inflammation and endoplasmic reticulum
stress [91], major hallmarks of these diseases, were shown
to increase circulating BCAA levels by reducing rates of
BCAA oxidation in adipose tissue and by enhancing skeletal
muscle protein degradation [83]. Furthermore, elevated
intake of BCAA was associated, independently of genetics,
with lower insulin resistance, inflammation, blood pressure,
and adiposity-related metabolites in female twins [92]. Such
beneficial BCAA actions to metabolic health were also seen
in several studies in rodents, where high BCAA intake was
associated with reductions in body weight, adiposity, and
glucose intolerance in diet-induced obese mice [93, 94].
Along with its beneficial effects on glucose homeostasis,
BCAA were shown to exert anti-inflammatory actions.
Indeed, elevated intake of BCAA was associated with reduc-
tions in muscle damage and inflammation during intensive
exercise training [94], in hepatic steatosis and inflammation
induced by diet-induced obesity [95, 96], and in chronic
white adipose tissue and liver inflammation and early-phase
hepatic tumorigenesis associated with obesity [97]. Extend-
ing those findings, elevating blood BCAA levels through the
deletion of the mitochondrial branched-chain aminotrans-
ferase (BCATm) in mice was shown to attenuate the cata-
bolic and proinflammatory effects of LPS and improve
survival in response to bacterial infection [98].
Although the mechanisms by which BCAA modulate
inflammation are not completely defined, it may involve the
activation of the amino acid sensor mTORC1, a multiprotein
complex composed by the highly conserved serine-threonine
kinase mTOR as its catalytic core, along with the accessory
proteins regulatory-associated protein of mTOR (Raptor),
mammalian lethal with Sec13 protein 8 (mLST8), DEP
domain-containing mTOR-interacting protein (DEPTOR),
proline-rich Akt substrate 40 (PRAS40), and Tti1/Tel2 com-
plex proteins [18]. The BCAA leucine activates mTORC1 by
inducing its translocation to the lysosomes and interaction
with the GTP-bound protein Ras homolog enriched in the
brain (Rheb). This requires leucine binding to sestrin 2 and
activation of small GTPases denominated as Ras-related
GTP-binding protein (Rags), through a process that involves
the protein complexes GAP activity towards Rags (GATOR)
1 and 2 and the Ragulator [18, 99]. Importantly, mTORC1’s
major cellular function is to coordinate processes such as cell
growth, proliferation, metabolism, autophagy, and survival
according to nutrient and growth factor availability [18].
In addition to amino acids and growth factors,
mTORC1 activity is also upregulated by proinflammatory
mediators such as LPS via TLR-4-mediated activation of
either IKKβ [100, 101] or PI3K-Akt [102, 103] and by the
anti-inflammatory cytokines IL-4 and IL-13 [104], indicat-
ing that this complex may have a role in the regulation of
inflammation and immune function. Indeed, pharmacolog-
ical mTORC1 inhibition with the macrolide rapamycin is
associated with an exacerbation of obesity-associated adipose
tissue inflammation, as evidenced by the enhanced tissue
recruitment and polarization of macrophages to a proin-
flammatory phenotype and expression of proinflammatory
cytokines IL-1β and TNF-α [104, 105]. In accordance to
these findings, mTORC1 inhibition with rapamycin was
shown to enhance the spontaneous polarization of human
monocytes in vitro and peripheral blood mononuclear cells
in vivo to a proinflammatory profile [106, 107]; such a
response is also seen in murine bone marrow-derived macro-
phages in vitro [104]. Importantly, Raptor deletion and
therefore mTORC1 deficiency in adipocytes, but not myeloid
cells [108], promoted adipose tissue inflammation, NLRP3-
inflammasome activation, leukocyte recruitment, and local
cytokine production [109]. Interestingly, this inflammatory
response, which occurred despite of a drastic reduction in
adipose tissue mass, was mediated by an increase in the local
production of ceramides [109] (Figure 2).
The effects of mTORC1 constitutive activation in embry-
onic fibroblasts and macrophages have also been investi-
gated reporting contrasting results. Constitutive mTORC1
activation through the inactivation of either TSC1 or TSC2
in human monocytes, murine myeloid cells, and embryonic
fibroblasts was shown to (1) limit the inflammatory response
by blocking LPS-induced NFκB activation and increasing
IL-10 production [107], (2) induce in a cell autonomous
manner granuloma formation and lung and liver infiltration
of alternatively activated M2 macrophages and reduce lung
iNOS [110], (3) increase the activity of the energy sensor
AMPK that exerts anti-inflammatory actions [111], and (4)
protect from diet-induced obesity and adipose tissue inflam-
mation by promoting the polarization of adipose tissue-
resident macrophages to a M2 phenotype (Paschoal et al.,
unpublished observations). Noteworthily, a recent study
found that the Akt-mTORC1 pathway is an important medi-
ator of macrophage polarization to a M2 phenotype induced
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by IL-4, through a mechanism that involves activation of
ATP-citrate lyase, histone acetylation, and transcriptional
induction of a subset of M2 genes [112]. In contrast to those
findings, however, Tsc1-deficient bone marrow-derived mac-
rophages (BMDM) were refractory to M2 polarization
induced by IL-4 and displayed enhanced M1 polarization,
nitric oxide (NO) production, and cytokine secretion
induced by toll-like receptor ligands [113, 114]. Surprisingly,
another study found that Tsc1-deficient macrophages exhib-
ited enhanced polarization to both M1 and M2 phenotypes
both at steady-state condition and induced by either LPS or
IL-4 [115].
In spite of the apparent contradictory findings, the sce-
nario emerging from the aforementioned studies is that
mTORC1 is an important mediator of both proinflamma-
tory M1 and anti-inflammatory M2 macrophage responses
(Figure 3). Indeed, this is in accordance with mTORC1’s
role in the regulation of processes such as protein, lipid
and nucleotide syntheses, autophagy, and lysosome forma-
tion that are vital to macrophages independently of their
phenotype. Accordingly with this notion, mTORC1 activity
is increased by proinflammatory molecules (LPS, TNF-α,
and IFN-γ) in M1 macrophage polarization [100, 102, 104],
as well as by the M2 macrophage-promoting cytokines (IL-
4 and IL-13) [104, 112]. Furthermore, mTORC1 induces
metabolic processes that are important for M1 and M2
macrophage functions, namely, aerobic glycolysis and oxi-
dative metabolism, respectively, through mechanisms that
involve activation of hypoxic-inducible factor 1α (HIF-1α)
in the former (M1 aerobic glycolysis) and the peroxisome
proliferator-activated receptor γ (PPARγ), PPAR coativactor
1α (PGC1α), and mitochondrial biogenesis in the latter (M2
oxidative metabolism) [116]. Altogether, these findings sug-
gest that mTORC1 is an important mediator of both classic
M1 and alternative M2 macrophage polarizations, exerting
its functions according to the underlying stimuli context
(Figure 3). In addition to macrophages, mTORC1 seems to
play an important role regulating T lymphocyte proliferation,
migration, differentiation, metabolism, and activation as ele-
gantly reviewed before [117].
Similarly to complex 1, mTORC2 is also activated by
both M1 (LPS and IFN-γ) and M2 (IL-4 and IL-13) inducers
playing an important role in regulation of macrophage polar-
ization and function (Figure 4). More specifically, deletion of
rapamycin-insensitive companion of mTOR (RICTOR) and
therefore mTORC2 deficiency in myeloid cells was shown
to enhance both polarization of bone marrow-derived
macrophages to the M1 profile and the proinflammatory
cytokine secretion induced by LPS and other TLR ligands
and to reduce the expression of M2-related genes [103].
Furthermore, mice with mTORC2 disruption in myeloid
cells had higher circulating TNF-α levels and mortality
in a model of acute septic shock induced by high dose
of LPS [103]. Mechanistically, this enhanced M1 polariza-
tion induced by mTORC2 deficiency was attributed to
FOXO1 activation due to reduced Akt activity and there-
fore enhanced transcription of proinflammatory genes
[118]. Subsequent studies have also shown that mTORC2
is essential for proper bone marrow-derived macrophage
polarization to a M2 profile. Indeed, mTORC2-deficient
M2 macrophages were shown to display impaired glucose
metabolism and reduced PPARγ content, mitochondrial bio-
genesis, and fatty acid oxidation, effects that are mediated by
Akt and, at least in part, by the transcriptional factor inter-
feron regulatory factor 4 (IRF4) [119].
1.5. Fatty Acid Excess and Inflammation. Evidence suggests
that lipids, especially fatty acids, play an important role not
only in obesity development but also as a linking factor
between the excessive adiposity and development of associ-
ated diseases [120]. Indeed, elevated intake of diets contain-
ing high amounts of saturated fatty acids induces obesity
and its major complications including inflammation, insulin
resistance, and ectopic lipid deposition, among others.
Recent studies, however, have indicated that more important
than quantity, diet fatty acid composition has major implica-
tions in the development of “metainflammation.” High
intake of diets rich in saturated fatty acids, for instance, acti-
vates the innate immune toll-like receptor 4 (TLR4) promot-
ing chronic low-grade inflammation, insulin resistance, and
cardiovascular disease [121]. In the same line, ω-6 polyun-
saturated fatty acid-enriched diets were shown to be proin-
flammatory and deleterious to the cardiovascular function
[121, 122]. In spite of the deleterious effects of saturated
and ω-6 polyunsaturated fatty acids to metabolic health,
other types of lipids have preventive and/or therapeutic
properties that could be explored to counteract metabolic
diseases. Among beneficial lipids, ω-3 polyunsaturated and
short-chain fatty acids were demonstrated to have anti-
inflammatory, anti-carcinogenic, hypolipidemic, and weight
loss-inducing properties [123, 124]. Below, we discuss the
modulation of “metainflammation” by specific types of fatty
acids (Figure 5).
1.6. Saturated Fatty Acids (SFAs). Saturated fatty acids such
as lauric (C12:0), miristic (C14:0), palmitic (C16:0), and stea-
ric (C18:0) are commonly found in foods of animal source
such as dairy products and meat, and some vegetables as
coconut and palm oil, being therefore the most prevalent
saturated fatty acids found in human diet. Many studies
have associated an elevated intake of saturated fatty acids
with a higher prevalence of obesity, cardiovascular disease,
diabetes, and insulin resistance, diseases that share chronic
low-intensity inflammation as a common feature [125].
ADIPOSE tissue
inflammation
NLRP3
inflammasome
Ceramides and ROS
Adipocyte mTORC1
deficiency
Figure 2: Mechanisms underlying adipose tissue chronic
inflammation induced by mTORC1 deficiency in adipocytes. ROS:
reactive oxygen species.
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Therefore, since 1961, the American Heart Association rec-
ommends a reduction in the intake of foods rich in satu-
rated fatty acids aiming to reduce the prevalence of those
chronic metabolic diseases [126].
At the molecular level, saturated fatty acids promote
inflammation through several mechanisms that include acti-
vation of the TLR4-IKK-NFκB signaling pathway and
NLRP3 inflammasome, enhanced ROS production and oxi-
dative stress, mitochondrial dysfunction, ER stress, accumu-
lation of diacylglycerol and ceramides, and PKC activation,
among others [63, 127–132]. Saturated fatty acids are potent
activators of the pattern recognition receptor TLR4, which is
also activated by LPS and others PAMPs and DAMPs and
has a major role in the regulation of innate immune response
[128, 133, 134]. Activation of TLR4 by saturated fatty acids
elicits, through the activation of NFκB, the secretion of sev-
eral proinflammatory cytokines such as TNF-α, IL-6, and
MCP-1, which are involved in the development of obesity-
associated inflammation and insulin resistance [128, 133,
134]. In addition, saturated fatty acids were shown to activate
NLRP3 inflammasome-mediated IL-1β production in mac-
rophages, such an effect that seems to involve AMPK inacti-
vation, autophagy inhibition, and enhanced mitochondrial
ROS production [129].
In addition to inflammatory signaling, chronic tissue
exposure to high levels of saturated fatty acids may promote
insulin resistance by increasing tissue content of the lipids
diacylglycerol and ceramides. Diacylglycerol accumulation
promotes insulin resistance by activating the PKCΘ and ε
impairing IRS tyrosine phosphorylation and therefore down-
stream insulin signaling [135]. Ceramides, on the other hand,
consist of a family of lipids structurally formed by a sphingo-
sine base bound to a fatty acid that promote insulin resistance
by two nonmutually exclusive mechanisms, involving either
the allosteric activation of protein phosphatase 2A (PP2A),
which dephosphorylates and inhibits Akt [136], or the activa-
tion of atypical PKC λ/ζ, which phosphorylates Akt pleck-
strin domain at residue 34 impairing its translocation to the
membrane and subsequent activation [137, 138]. Ceramides
have been also shown to modulate inflammatory processes
LPS and TLR4 IL-4 and IL-3Growth factors
PI3K
PIP3
PKB/Akt
TSC1/TSC2
RAPTOR
mTOR
mTORC1
M1 macrophages M2 macrophages
mLST8 DEPTOR PRAS40
Tti1/Tel2
PDK1mTORC2IKK
PPAR and PGC1
Mitochondrial biogenesis
Fatty acid oxidation
ATP citrate lyase (ACLY)
Glycolysis
HIF-1𝛼
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?
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Figure 3: mTORC1 is activated in both M1 and M2 polarization and regulates important metabolic processes at both conditions. AA: amino
acids; ACLY: ATP citrate lyase; HIF-1α: hypoxic inducible factor 1α; IL-4: interleukin 4; IL-13: interleukin 13; PGC1α: PPARγ coactivator 1α;
PPARγ: peroxisome proliferator-activated receptor γ; TLR4: toll like receptor 4.
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displaying either pro- or anti-inflammatory responses, as ele-
gantly reviewed before [139]. Briefly, proinflammatory
actions of ceramides involve activation of TLR4 signaling as
a result of ceramide interaction with this receptor, formation
of TLR4-lipid raft complex, and activation of NLRP3
inflammasome-mediated IL-1β and IL-18 production [139].
1.7. Monounsaturated Fatty Acids (MUFAs). In contrast to
their saturated counterparts, elevated intake of monounsat-
urated fatty acids is associated with reduced adipocyte
hypertrophy, adipose tissue infiltration of proinflammatory
macrophages, and inflammation and improved insulin
sensitivity [140–142]. In line with these findings, oleic
acid (C18:1), the most abundant monounsaturated fatty
acid found in human diet, promotes the secretion of the
anti-inflammatory adipokine adiponectin and impairs the
proinflammatory resistin in 3T3-L1 adipocytes [143]. Fur-
thermore, diet supplementation with macadamia oil, a rich
source of oleic acid, improves lipid metabolism and glu-
cose homeostasis in diet-induced obese mice [144, 145].
Although oleic acid is the major fatty acid found in macada-
mia oil, this nut is also an important natural source of the
monounsaturated fatty acid palmitoleic acid (C16:1). This
fatty acid, which can be obtained either from diet or from
endogenous synthesis by stearoyl-CoA desaturase- (SCD-)
1 mainly in adipose tissue and liver, was shown to enhance
whole-body glucose disposal and attenuate hepatic steatosis
in diet-induced obese mice [146, 147] and protect β-cell
from death induced by palmitic acid [148, 149]. In line
with those findings, a two-week supplementation with
palmitoleic acid improved glucose homeostasis and insulin
sensitivity, reduced hepatic steatosis, and increased skeletal
muscle fatty acid oxidation in diet-induced obese mice [150].
In addition, palmitoleic acid also increased hepatic oxidative
metabolism by activating the AMPK-fibroblast growth fac-
tor- (FGF-) 21-peroxisome proliferator-activated receptor
(PPAR) α axis [151]. In addition to these beneficial metabolic
actions, palmitoleic acid was recently shown to have anti-
inflammatory properties. Indeed, macrophages pretreated
with palmitoleic acid secrete less proinflammatory cytokines
after either LPS or palmitic acid treatment [152, 153] and dis-
played reduced macrophage polarization to a M1 phenotype
in part due to AMPK activation [154]. Altogether, these
findings support a possible utilization of palmitoleic acid
supplementation as a nonpharmacological strategy to reduce
obesity-associated chronic low-grade inflammation [155].
Interestingly, palmitoleic acid was also shown to enhance
lipolysis, glucose uptake, and GLUT-4 content in adipocytes,
such effects that are mechanistically induced by PPARα and
AMPK activation, respectively [156, 157]. Whether palmito-
leic acid also has anti-inflammatory actions in white adipose
tissue needs to be investigated.
1.8. ω-6 Polyunsaturated Fatty Acids. In addition to the high
content of saturated fatty acids, another main feature defin-
ing the Western diet is the elevated ω-6 and low ω-3 polyun-
saturated fatty acid contents [158]. Evidence indicates that
this high ω-6/ω-3 ratio dietary pattern is one of the main
causes of the rise in obesity and associated metabolic diseases
seen in the last decades [159]. Linoleic acid, the most abun-
dant ω-6 fatty acid in theWestern diet, has important actions
on cholesterol metabolism, as well as on inflammation. More
specifically, linoleic acid was shown to lower blood choles-
terol levels by increasing both hepatic clearance of low-
density lipoprotein (LDL) [160] and production of bile acids
and to be proinflammatory by activating NFκB in endothelial
cells [161], although this does not seem to be reflected by sys-
temic markers of inflammation [162]. Linoleic acid can be
enzymatically converted to arachidonic acid, a ω-6 fatty acid
that acts as the precursor for the synthesis of two classes of
lipid mediators known as eicosanoids (prostaglandins,
prostacyclins, thromboxane, and leukotrienes) and endocan-
nabinoids (anandamide and 2-arachidonoylglycerol, among
others). Eicosanoids are potent regulators of inflammation
and immune function, being therefore implicated in the
development of chronic metabolic diseases such as obesity,
insulin resistance, and cancer [159]. Indeed, recent studies
have shown that the eicosanoid leukotriene B4 promotes adi-
pose tissue inflammation by inducing tissue macrophage
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Figure 4: mTORC2 is activated in both M1 and M2 polarization
and regulates important metabolic processes at both conditions. IL-
1β: interleukin 1β; IL-4: interleukin 4; IL-13: interleukin 13; IRF4:
interferon regulatory factor 4; LPS: lipopolysaccharide; PKB: protein
kinase B; PPARγ: peroxisome proliferator-activated receptor γ;
TLR4: toll-like receptor 4; TNF-α: tumor necrosis factor-α.
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chemotaxis and polarization to the proinflammatory M1
profile, as well as insulin resistance in the liver and skeletal
muscle [163]. Interestingly, opposite effects were seen upon
treatment with the eicosanoid lipoxin A4, which reduced
adipose tissue inflammation as evidenced by diminished tis-
sue expression of proinflammatory cytokines and higher
macrophage polarization to the anti-inflammatory M2 pro-
file [164]. These findings indicate that different eicosanoids
have distinct roles in the regulation of adipose tissue
inflammation and therefore in the development of obesity-
associated insulin resistance.
1.9. ω-3 Polyunsaturated Fatty Acids. It has been known since
the 1980s that fish oil, which is rich in the ω-3 polyunsatu-
rated fatty acids eicosapentaenoic acid (EPA) (C20:5, ω-3)
and docosahexaenoic acid (DHA) (C22:6, ω-3), has many
beneficial health effects. Indeed, increased whole-body ω-3
polyunsaturated fatty acid availability either genetically or
through dietary supplementation is associated with hypotri-
glyceridemia [165], improvement in cardiovascular health
by diminishing platelet aggregation and thromboxane levels
[166, 167], and attenuation of systemic inflammation [168,
169]. More recently, ω-3 polyunsaturated fatty acids were
also shown to protect mice from diet-induced obesity, insulin
resistance, hepatic steatosis, and tumorigenesis; such effects
were attributed at least in part to the anti-inflammatory
properties of these fatty acids [123, 170]. Several mechanisms
have been proposed to account for the anti-inflammatory
actions of ω-3 polyunsaturated fatty acids including the acti-
vation of the plasma membrane G protein-coupled receptor
120 (GPR120) [171], activation of the nuclear receptor
PPARγ [172], inhibition of the conversion of ω-6 fatty acids
into eicosanoids [159], alterations in plasmamembrane com-
position, fluidity and signaling [173], and induction of the
synthesis of proresolution lipid mediators such as resolvins,
protectins, and maresins [174]. Among these, recent studies
have shown that activation of GPR120, a receptor mainly
expressed in adipocytes and macrophages, may be essential
to the anti-inflammatory actions of ω-3 polyunsaturated fatty
acids. Indeed, both EPA and DHA were shown to impair
LPS-induced JNK activation and TNF-α and IL-6 secretion
by RAW 264.7 cells and 3T3-L1 adipocytes in vitro through
the activation of GPR120 [171]. In line with those findings,
mice deficient in GPR120 were resistant to the anti-
inflammatory actions and the improvement in whole-body
glucose homeostasis induced by the intake of diet rich in ω-
3 polyunsaturated fatty acids [171]. Two recent studies, how-
ever, have challenged the notion that GPR120 activation is
mandatory for those ω-3 polyunsaturated fatty acid actions.
These studies have shown that intake of diet rich in ω-3 poly-
unsaturated fatty acids was equally effective in reducing body
weight gain, improving glucose homeostasis and attenuating
inflammation in a new generated mice deficient in GPR120
and wild-type controls [175, 176].
Another mechanism by which ω-3 polyunsaturated fatty
acids may reduce inflammation is by enhancing the synthesis
of proresolution lipid mediators, namely, protectins, resol-
vins, and maresins. Both EPA (e-series) and DHA (d-series)
are precursors for the synthesis of these mediators [177],
which have been shown to control the magnitude and dura-
tion of inflammatory processes in several rodent models of
chronic diseases [174]. In line with this notion, the resolvin
E1 and protectin D1 were shown to improve insulin sensitiv-
ity and reduce hepatic steatosis and adipose tissue inflamma-
tion in diet-induced obese mice [178], whereas resolvin D1
improved glucose tolerance, increased adiponectin secretion,
and reduced adipose tissue macrophage recruitment and for-
mation of crown-like structures in genetically obese db/db
mice [179]. Furthermore, protectin DX improved glucose
homeostasis in db/dbmice by promoting IL-6 secretion from
skeletal muscle without affecting white adipose tissue inflam-
mation [180]. Further studies characterizing the biological
function of already described and new metabolites from
EPA and DHA are required to explore the promising usage
of these lipids in the prevention and/or treatment of chronic
inflammatory diseases.
1.10. Short-Chain Fatty Acids (SCFA). The short-chain fatty
acids acetate (C2), propionate (C3), and butyrate (C4) are
produced at the intestine by anaerobic fermentation of
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Figure 5: General overview of the mechanisms by which different fatty acids modulate inflammation. AMPK: AMP-activated protein kinase;
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nondigestible dietary fibers, being readily absorbed and used
as energy source by colonocytes and by other body tissues
including liver and muscle [181]. In addition to their role as
metabolic substrates, short-chain fatty acids regulate several
aspects of inflammatory processes such as the recruitment
of circulating leukocytes in the inflammatory site, production
of chemokines and cytokines, expression of adhesion mole-
cules, production of eicosanoids and reactive oxygen species,
and lymphocyte proliferation and differentiation [124].
Studies evaluating the effects of short-chain fatty acids in
animal models of inflammatory diseases including acute kid-
ney injury, obesity, and T2D indicate that these molecules
are potent anti-inflammatory agents [182, 183]. Indeed,
sodium butyrate administration to obese and diabetic db/db
mice markedly attenuated adipose tissue inflammation as
evidenced by reduced tissue lymphocyte infiltration, cyto-
kine expression and NLRP3 inflammasome activity, and
improved glucose homeostasis [184]. Furthermore, propio-
nate reduced the proinflammatory response and cytokine
secretion induced by LPS in human adipose tissue explants
and macrophages [185], whereas butyrate activates the
anti-inflammatory Treg cells suppressing the secretion of
cytokines via activation of membrane G protein-coupled
receptors GPR43/FFAR2 [186]. These receptors, which are
mainly expressed in adipose tissue (adipocytes), intestines,
and immune cells and signals through Gq and Gi/o, ERK,
MAPK, and intracellular Ca2+, are important mediators of
short-chain fatty acid actions [187]. Noteworthily, as recently
reviewed [188], inconsistent results have been obtained in
studies with GPR43 deletion in mice, which precludes a full
appreciation of the role of these receptors in chronic inflam-
matory conditions. Finally, short-chain fatty acids were also
shown to impair LPS-induced production of nitric oxide
and proinflammatory cytokines in the macrophage cell line
RAW264.7; such effect seems to involve inhibition of NFκB
signaling [189].
In addition to inflammation, short-chain fatty acids
also have important effects on energy homeostasis. Recent
studies have found that diet enrichment with 5% short-
chain fatty acids reduced body weight, adiposity, and
hepatic steatosis in diet-induced obese mice by downregulat-
ing the activity of the nuclear receptor PPARγ [182], whereas
nanoparticle-delivered acetate reduced diet-induced body
weight gain, hepatic steatosis, and adiposity by enhancing
hepatic mitochondrial function and inducing adipose tissue
browning [190].
1.11. Newly Identified Lipids and Inflammation. The develop-
ment of highly-sensitive OMICS techniques (lipidomic,
metabolomic, genomic, transcriptomic, epigenomic, and
proteomic) in the last decades has allowed the large-scale
study of different classes of molecules in distinct compart-
ments and conditions. Among those, metabolomic profiling
and lipidomic profiling have emerged as promising method-
ologies to uncover new metabolites/lipids that either predict
or are involved in the development of insulin resistance/
T2D. Recently, a metabolomic study of the plasma of 399
nondiabetic subjects with a wide range in degree of insulin
sensitivity and glucose tolerance identified a group of three
metabolites (α-hydroxybutyrate, oleate, and L-glycerylpho-
sphorylcholine) that together could predict the development
of insulin resistance [191]. Furthermore, lipidomic character-
ization of obese, but insulin-sensitive mice, identified a class
of endogenously synthesized lipids denominated as branched
fatty acid esters of hydroxy fatty acids (FAHFAs) that
improves glucose homeostasis and insulin sensitivity and
reduces adipose tissue inflammation in diet-induced obese
mice [192]. These are only two among many examples of
OMICS application to the study of different aspects of
obesity-associated inflammation and insulin resistance.
These highly sensitive techniques will help us both to unveil
the many molecules involved in the development of these
diseases and provide major insights in the novel strategies
to prevent and treat them.
2. Conclusions
There is an established body of literature indicating that
nutrients and nutrient sensors are important players
involved in the development and maintenance of obesity-
associated inflammation and insulin resistance. In these
studies, important advances have been made in the charac-
terization of the mechanisms by which nutrients exert their
actions, resulting in the unveiling of new therapeutic targets
for the treatment of metabolic diseases. Despite this prog-
ress, we are far from having the complete understanding
about the complex interaction between nutrients and obe-
sity. Indeed, with the advances of techniques such as meta-
bolomics and lipidomics, new nutrient-related molecules
are being discovered and characterized for their potential
implication in the development of obesity and insulin
resistance. The characterization of nutrients and derived
metabolites that present proresolution properties towards
obesity-associated chronic low-grade systemic inflamma-
tion is of major importance if we are to develop novel,
effective therapies to prevent metabolic and cardiovascular
complications associated with this disease.
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